“As we eagerly anticipate initiating a Phase 2/3 efficacy trials this summer, an animal challenge is currently the closest thing we have to testing a vaccine’s efficacy when confronting a live virus" - INO-4800

 https://homelandprepnews.com/stories/53282-inovios-covid-19-vaccine-candidate-shows-promise-in-trials/

https://homelandprepnews.com/stories/53282-inovios-covid-19-vaccine-candidate-shows-promise-in-trials/

“As we eagerly anticipate initiating a Phase 2/3 efficacy trials this summer, an animal challenge is currently the closest thing we have to testing a vaccine’s efficacy when confronting a live virus.

We are very encouraged with the duration of protection that INO-4800 demonstrated in this NHP study and look forward to reassessing its impact on durability of response at 12 months out from our other ongoing non-human primate and animal challenge studies,” Dr. Kate Broderick, Inovio’s senior vice president, research & development, said.

“In addition to safety and efficacy, it is essential that any vaccine targeting SARS-CoV-2 generates a relevant durability of response,” Broderick added.

“A vaccine that only provides protection for a very short period of time is not going to realistically solve the problem of this #pandemic.”

A separate study evaluating the durability of INO-4800 at 12 months after vaccination is currently underway. INO-4800 is part of the federal government’s Operation Warp Speed.

#SARSCoV2 #animalModels #animalChallenge #LIVEVirus #wildVirus #INO4800